Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA clears Inova's Luminex-based diagnostic kit:

This article was originally published in Clinica

Executive Summary

Inova Diagnostics has gained US FDA 510(k) marketing clearance for an immunoassay that can simultaneously measure four of the most common autoantibodies - Sm, RNP, SS-A and SS-B - found in systemic autoimmune disorders. The QUANTA Plex ENA Profile 4 is based on a testing technology, called LabMAP, developed by Luminex. LabMAP, which is also cleared in the US, combines microsphere-based assays with small lasers, advanced digital signal processors and software to offer greater speed, precision and flexibility over current bioassay technologies, Inova claims. The San Diego, California firm says it plans to expand its QUANTA Plex product line. It will pay Luminex a royalty based on sales of their LabMAP-based products.

You may also be interested in...

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail

Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts